Author(s): Mansimran Kaur Randhawa, Aruna Bhatia, Praveen Pal Balgir, Sheikh Abid Ali
Elevated blood cholesterol is a well known major risk factor for coronary heart diseases. In this respect, the ingestion of probiotic lactic acid bacteria might be a natural way to decrease the serum cholesterol in humans. Recent studies show that bacterial DNA containing immunostimulatory “CpG motifs” interact with Toll-like receptor 9 to initiate an immunostimulatory cascade that culminates in the maturation, differentiation and/or proliferation of multiple cell types leading to beneficial health effects. The present study was designed to compare the hypocholesteremic effect of probiotic bacteria and its isolated DNA’s in swiss albino mice. In the experimental design, animals were divided into VII groups such as Untreated control, Positive control, Drug control (Atorvastatin ,100mg/kg, b.wt.),LB 405 (109cells day-1 mouse-1 as oral dose) ,DNA LB 405 (75µg mL-1 mouse-1), LB 405 + Atorvastatin, DNA LB 405 + Atorvastatin .The analysis of the results revealed that the DNA of probiotic strain alone or in the combination with standard drug reduced the total cholesterol levels 1.3 and 1.9 times more than probiotic alone or in combination with standard drug. It is concluded that DNA of probiotic is better and safer alternative therapeutic agent than the probiotics alone especially in those subjects where probiotics cannot be given.